Company intelligence / Profile preview

Ampersand Biomedicines

Boston, Massachusetts, USAampersand.bio ↗

Ownership: Private
Development stage: Preclinical

Overview

Lead candidate AMP-410 showed strong efficacy in preclinical models of hard-to-treat cancers compared to four other clinical-stage immunotherapies. AMP-410 monotherapy achieved 90% tumor-free survival in colorectal cancer and extended survival in melanoma models; when combined with anti-PD-1, it drove 100% tumor-free survival in colorectal cancer.[6]

Therapeutic areas: OncologyImmunologyEndocrinology
Modalities: BiologicsAND-Body™ Therapeutics (programmable biologic medicines)
Industry: Biotech

Drug pipeline

2 assets

AMP-410

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Eli Lilly & CompanyPfizerPioneering Medicines (Flagship's in-house drug discovery and development unit)

Beyond the preview

Go deeper on Ampersand Biomedicines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ampersand Biomedicines.

Explore the full profile